Rituximab plus Short-Duration Chemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan as First-Line Treatment for Patients with Follicular Non-Hodgkin Lymphoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium

Hainsworth, John D.; Spigel, David R.; Markus, Tiffanie; Shipley, Dianna; Thompson, Dana S.; Rotman, Richard; Dannaher, C.; Greco, F. Anthony

doi:10.3816/clm.2009.n.044

Cited by 57 publications

(34 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The trial, however, enrolled only 15% of patients receiving rituximab as part of the induction regimen. This conclusion is further supported by several phase II studies where ibritumomab tiuxetan was given to patients after remission induction with R-CHOP [43,44] or FNR [45,46].…”

Section: Issue 4: Assessment Of Response (Consensus-based Recommendatsupporting

confidence: 51%

SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma

et al. 2013

View full text Add to dashboard Cite

By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issued in 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmunotherapy in patients with Stage III-IV disease and/or high tumor burden. Maintenance rituximab was also recommended in responding patients. In patients relapsing after an interval longer than 12 months from frontline therapy, we recommended chemoimmunotherapy with non cross-resistant regimens followed by rituximab maintenance. High dose chemotherapy followed by hematopoietic stem cell transplant was recommended for young fit patients who achieve a response after salvage chemoimmunotherapy. Am. J. Hematol. 88:185-192, 2013. V

show abstract

Section: Issue 4: Assessment Of Response (Consensus-based Recommendatsupporting

confidence: 51%

SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…These results, albeit from a small subgroup analysis, point to the fact that zevalin is active in patients pretreated with rituximab chemotherapy. This conclusion is further supported by several phase II studies where zevalin was given to patients after remission induction with R-CHOP [9,10] or R-FND [11]. So far, in the FIT study overall survival (OS) is not different between the two groups.…”

Section: Zevalin Consolidation After Induction (Immuno)chemotherapysupporting

confidence: 62%

VIII. Radioimmunotherapy in malignant lymphoma: an underused tool?

Hagenbeek

2011

Annals of Oncology

View full text Add to dashboard Cite

“…Recent work has emphasized the use of RIT consolidation after chemotherapy in the frontline management of patients with indolent lymphoma. Consolidation RIT yields dramatic improvements in CR when compared with chemotherapy alone (19,(25)(26)(27). In addition, these patients may be considered for consolidation EBRT to sites of BD that are sluggishly responsive to chemotherapy.…”

Section: Discussionmentioning

confidence: 97%